The druggable schizophrenia genome: from repurposing opportunities to unexplored drug targets. Lago, S. G. & Bahn, S. npj Genomic Medicine, 7(1):1–13, March, 2022. Number: 1 Publisher: Nature Publishing Group![The druggable schizophrenia genome: from repurposing opportunities to unexplored drug targets [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper doi abstract bibtex There have been no new drugs for the treatment of schizophrenia in several decades and treatment resistance represents a major unmet clinical need. The drugs that exist are based on serendipitous clinical observations rather than an evidence-based understanding of disease pathophysiology. In the present review, we address these bottlenecks by integrating common, rare, and expression-related schizophrenia risk genes with knowledge of the druggability of the human genome as a whole. We highlight novel drug repurposing opportunities, clinical trial candidates which are supported by genetic evidence, and unexplored therapeutic opportunities in the lesser-known regions of the schizophrenia genome. By identifying translational gaps and opportunities across the schizophrenia disease space, we discuss a framework for translating increasingly well-powered genetic association studies into personalized treatments for schizophrenia and initiating the vital task of characterizing clinically relevant drug targets in underexplored regions of the human genome.
@article{lago_druggable_2022,
title = {The druggable schizophrenia genome: from repurposing opportunities to unexplored drug targets},
volume = {7},
copyright = {2022 The Author(s)},
issn = {2056-7944},
shorttitle = {The druggable schizophrenia genome},
url = {https://www.nature.com/articles/s41525-022-00290-4},
doi = {10.1038/s41525-022-00290-4},
abstract = {There have been no new drugs for the treatment of schizophrenia in several decades and treatment resistance represents a major unmet clinical need. The drugs that exist are based on serendipitous clinical observations rather than an evidence-based understanding of disease pathophysiology. In the present review, we address these bottlenecks by integrating common, rare, and expression-related schizophrenia risk genes with knowledge of the druggability of the human genome as a whole. We highlight novel drug repurposing opportunities, clinical trial candidates which are supported by genetic evidence, and unexplored therapeutic opportunities in the lesser-known regions of the schizophrenia genome. By identifying translational gaps and opportunities across the schizophrenia disease space, we discuss a framework for translating increasingly well-powered genetic association studies into personalized treatments for schizophrenia and initiating the vital task of characterizing clinically relevant drug targets in underexplored regions of the human genome.},
language = {en},
number = {1},
urldate = {2022-05-27},
journal = {npj Genomic Medicine},
author = {Lago, Santiago G. and Bahn, Sabine},
month = mar,
year = {2022},
note = {Number: 1
Publisher: Nature Publishing Group},
keywords = {Genome, Pharmaceutics, Schizophrenia, Target identification},
pages = {1--13},
}
Downloads: 0
{"_id":"S4DPP3Pje7LsMLPtB","bibbaseid":"lago-bahn-thedruggableschizophreniagenomefromrepurposingopportunitiestounexploreddrugtargets-2022","author_short":["Lago, S. G.","Bahn, S."],"bibdata":{"bibtype":"article","type":"article","title":"The druggable schizophrenia genome: from repurposing opportunities to unexplored drug targets","volume":"7","copyright":"2022 The Author(s)","issn":"2056-7944","shorttitle":"The druggable schizophrenia genome","url":"https://www.nature.com/articles/s41525-022-00290-4","doi":"10.1038/s41525-022-00290-4","abstract":"There have been no new drugs for the treatment of schizophrenia in several decades and treatment resistance represents a major unmet clinical need. The drugs that exist are based on serendipitous clinical observations rather than an evidence-based understanding of disease pathophysiology. In the present review, we address these bottlenecks by integrating common, rare, and expression-related schizophrenia risk genes with knowledge of the druggability of the human genome as a whole. We highlight novel drug repurposing opportunities, clinical trial candidates which are supported by genetic evidence, and unexplored therapeutic opportunities in the lesser-known regions of the schizophrenia genome. By identifying translational gaps and opportunities across the schizophrenia disease space, we discuss a framework for translating increasingly well-powered genetic association studies into personalized treatments for schizophrenia and initiating the vital task of characterizing clinically relevant drug targets in underexplored regions of the human genome.","language":"en","number":"1","urldate":"2022-05-27","journal":"npj Genomic Medicine","author":[{"propositions":[],"lastnames":["Lago"],"firstnames":["Santiago","G."],"suffixes":[]},{"propositions":[],"lastnames":["Bahn"],"firstnames":["Sabine"],"suffixes":[]}],"month":"March","year":"2022","note":"Number: 1 Publisher: Nature Publishing Group","keywords":"Genome, Pharmaceutics, Schizophrenia, Target identification","pages":"1–13","bibtex":"@article{lago_druggable_2022,\n\ttitle = {The druggable schizophrenia genome: from repurposing opportunities to unexplored drug targets},\n\tvolume = {7},\n\tcopyright = {2022 The Author(s)},\n\tissn = {2056-7944},\n\tshorttitle = {The druggable schizophrenia genome},\n\turl = {https://www.nature.com/articles/s41525-022-00290-4},\n\tdoi = {10.1038/s41525-022-00290-4},\n\tabstract = {There have been no new drugs for the treatment of schizophrenia in several decades and treatment resistance represents a major unmet clinical need. The drugs that exist are based on serendipitous clinical observations rather than an evidence-based understanding of disease pathophysiology. In the present review, we address these bottlenecks by integrating common, rare, and expression-related schizophrenia risk genes with knowledge of the druggability of the human genome as a whole. We highlight novel drug repurposing opportunities, clinical trial candidates which are supported by genetic evidence, and unexplored therapeutic opportunities in the lesser-known regions of the schizophrenia genome. By identifying translational gaps and opportunities across the schizophrenia disease space, we discuss a framework for translating increasingly well-powered genetic association studies into personalized treatments for schizophrenia and initiating the vital task of characterizing clinically relevant drug targets in underexplored regions of the human genome.},\n\tlanguage = {en},\n\tnumber = {1},\n\turldate = {2022-05-27},\n\tjournal = {npj Genomic Medicine},\n\tauthor = {Lago, Santiago G. and Bahn, Sabine},\n\tmonth = mar,\n\tyear = {2022},\n\tnote = {Number: 1\nPublisher: Nature Publishing Group},\n\tkeywords = {Genome, Pharmaceutics, Schizophrenia, Target identification},\n\tpages = {1--13},\n}\n\n","author_short":["Lago, S. G.","Bahn, S."],"key":"lago_druggable_2022","id":"lago_druggable_2022","bibbaseid":"lago-bahn-thedruggableschizophreniagenomefromrepurposingopportunitiestounexploreddrugtargets-2022","role":"author","urls":{"Paper":"https://www.nature.com/articles/s41525-022-00290-4"},"keyword":["Genome","Pharmaceutics","Schizophrenia","Target identification"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://api.zotero.org/users/6447874/collections/AWT385HL/items?key=EzirEtCHddAI8OiL0hFklGbe&format=bibtex&limit=100","dataSources":["eTsH756eicg6vxuG3","Rcf3ThCgN7ShBuzJy","tWgPDtt4MHxv5bMax","jEsWEe9RBbgbTMFzt","TvrStsceXSmGoKMJj","z4ASdQSCbDqBhbYkc"],"keywords":["genome","pharmaceutics","schizophrenia","target identification"],"search_terms":["druggable","schizophrenia","genome","repurposing","opportunities","unexplored","drug","targets","lago","bahn"],"title":"The druggable schizophrenia genome: from repurposing opportunities to unexplored drug targets","year":2022}